<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225988</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00054474</org_study_id>
    <nct_id>NCT04225988</nct_id>
  </id_info>
  <brief_title>Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in HLA Sensitized Kidney Transplant Recipients</brief_title>
  <official_title>A Prospective, Pilot Trial to Compare the Efficacy of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release on Suppression of Donor-Specific Antibodies in HLA Sensitized Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, controlled clinical trial designed to compare clinical
      outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus
      immediate tacrolimus among highly-sensitized kidney transplant recipients. Outcomes to be
      assessed include the incidence of biopsy-proven acute rejection at 12 months, the presence of
      de novo and pre-existing donor-specific HLA antibodies, estimated glomerular filtration rate,
      and the level of donor-derived cell-free DNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extended-release tacrolimus (Envarsus XR) received FDA approval in July, 2015 for the
      prevention of allograft rejection in kidney transplantation on the basis of two separate
      phase 3 trials of de novo and stable kidney transplant recipients that demonstrated
      non-inferiority to immediate-release tacrolimus for the composite outcome of death, graft
      failure, biopsy-proven acute rejection, or loss to follow-up within 12 months (1,2).

      Both phase 3 trials involved mostly low immunologic risk recipients with follow-up to one
      year. It has been previously shown that the incidence of de novo donor-specific antibodies
      (DSA) in the first year after kidney transplant in low-immunologic patients is low,
      developing in only 2%-11% of unsensitized de novo kidney transplant recipients (3-6).
      Donor-specific antibodies (DSA) are the primary mediator of antibody-mediated rejection and
      their development after transplant is a major risk factor for late allograft failure (7). It
      is now believed that antibody-mediated rejection is the most common cause of late allograft
      failure (8,9). However, neither of the two phase 3 trials were able to adequately assess the
      effect of Envarsus XR on the development of donor specific antibodies and therefore, the
      efficacy of Envarsus XR in higher immunologic risk recipients is not known. Therefore, a
      comparative study of extended- and immediate-release tacrolimus in highly-sensitized
      recipients is warranted.

      This is a randomized, open-label, controlled clinical trial designed to compare clinical
      outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus
      immediate tacrolimus among highly-sensitized kidney transplant recipients. Twenty patients
      will be enrolled, with ten assigned to each study arm. Outcomes to be assessed include the
      incidence of biopsy-proven acute rejection at 12 months, the presence of de novo and
      pre-existing donor-specific HLA antibodies, estimated glomerular filtration rate, and the
      level of donor-derived cell-free DNA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with biopsy-proven acute rejection at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of de novo donor-specific antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Mean number of de novo donor-specific antibodies per patient developing within the first post-transplant year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of persistent pre-existing donor-specific antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Mean number of pre-existing donor-specific antibodies per patient that persist at twelve months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean eGFR at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent donor-derived cell-free DNA at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Mean percentage donor-derived cell-free DNA at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent donor-derived cell-free DNA at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Mean percentage donor-derived cell-free DNA at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Extended-release tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate-release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-release tacrolimus</intervention_name>
    <description>Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.</description>
    <arm_group_label>Extended-release tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate-release tacrolimus</intervention_name>
    <description>Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.</description>
    <arm_group_label>Immediate-release tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recipient of a deceased or living donor kidney allograft

          2. Patients must have undergone desensitization with IVIG and rituximab with or without
             plasma exchange prior to transplant or be administered IVIG and rituximab
             peri-operatively (within seven days of transplant) post-transplant

          3. Age 18 and over

          4. Able to understand and provide informed consent

          5. At transplant, patient must have an acceptable crossmatch [as defined by a T- or
             B-flow crossmatch â‰¤ 225 median channel shift (MCS)] from a non-HLA identical donor. A
             negative crossmatch is defined as a T pronase flow crossmatch &lt; 70 MCS or a T- flow
             crossmatch &lt; 50 MCS and a B pronase flow crossmatch &lt;130 MCS or a B-flow crossmatch
             &lt;100 MCS.

        Exclusion Criteria:

          1. Recipients of a dual simultaneous kidney/liver, kidney/heart, kidney/lung, or
             kidney/pancreas transplant

          2. History of hypersensitivity to any of the study drug or to drugs of similar chemical
             classes

          3. Patients with a clinically significant systemic infection within 30 days prior to
             transplant

          4. Patients who have any history of a surgical or medical condition that may affect
             absorption of drug, such as severe diarrhea, active peptic ulcer disease, or
             uncontrolled diabetes mellitus, which in the opinion of the investigator at the time
             of enrollment, might significantly alter the absorption, distribution, metabolism
             and/or excretion of study medication.

          5. Women of childbearing potential who are either pregnant, lactating, planning to become
             pregnant during this trial, or with a positive serum or urine pregnancy test. Women of
             childbearing potential must be willing to agree to contraceptive practices.

          6. Patients who are PCR positive for hepatitis B, hepatitis C, or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noriko Ammerman, Pharm.D.</last_name>
    <phone>310-248-8186</phone>
    <email>noriko.ammerman@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edmund Huang, M.D.</last_name>
    <phone>310-248-6528</phone>
    <email>edmund.huang@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noriko Ammerman, Pharm.D.</last_name>
      <phone>310-248-8186</phone>
      <email>Noriko.Ammerman@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Edmund Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley C Jordan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Peng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Supreet Sethi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Vo, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norko Ammerman, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reiad Najjar, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L; Envarsus study group. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant. 2014 Dec;14(12):2796-806. doi: 10.1111/ajt.12955. Epub 2014 Oct 2.</citation>
    <PMID>25278376</PMID>
  </reference>
  <reference>
    <citation>Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, Budde K; MELT investigators. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013 Mar;13(3):760-9. doi: 10.1111/ajt.12035. Epub 2012 Dec 21.</citation>
    <PMID>23279614</PMID>
  </reference>
  <reference>
    <citation>Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 Feb 15;95(3):410-7. doi: 10.1097/TP.0b013e31827d62e3.</citation>
    <PMID>23380861</PMID>
  </reference>
  <reference>
    <citation>Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009 Nov;9(11):2532-41. doi: 10.1111/j.1600-6143.2009.02800.x.</citation>
    <PMID>19843031</PMID>
  </reference>
  <reference>
    <citation>Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, Cornell L, Stegall MD. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. Am J Transplant. 2017 Jun;17(6):1574-1584. doi: 10.1111/ajt.14161. Epub 2017 Jan 25.</citation>
    <PMID>27977905</PMID>
  </reference>
  <reference>
    <citation>Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, Karpinski M, Goldberg A, Storsley L, Rush DN, Nickerson PW. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015 Nov;15(11):2921-30. doi: 10.1111/ajt.13347. Epub 2015 Jun 10.</citation>
    <PMID>26096305</PMID>
  </reference>
  <reference>
    <citation>Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012 Apr 17;8(6):348-57. doi: 10.1038/nrneph.2012.81. Review.</citation>
    <PMID>22508180</PMID>
  </reference>
  <reference>
    <citation>SellarÃ©s J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012 Feb;12(2):388-99. doi: 10.1111/j.1600-6143.2011.03840.x. Epub 2011 Nov 14.</citation>
    <PMID>22081892</PMID>
  </reference>
  <reference>
    <citation>Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009 Nov;9(11):2520-31. doi: 10.1111/j.1600-6143.2009.02799.x.</citation>
    <PMID>19843030</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Edmund Huang</investigator_full_name>
    <investigator_title>Staff Physician II</investigator_title>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>rejection</keyword>
  <keyword>donor-specific antibodies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

